Novartis' Cosentyx (secukinumab) Receives NMPA's (CFDA) Approval for Patients with Plaque Psoriasis in Adults
Shots:
- The approval is based on P-III CAIN457A2318 study results assessing Cosentyx (300/150 mg- q4w) vs PBO in 543 patients with moderate-to-severe plaque PsO. Additionally- P-III study in China assessed Cosentyx (300mg- q4w) in 10 Psoriasis patients
- P-III CAIN457A2318 study results: @12 wks. PASI 75/90 (97.7%- 87.8%/ 80.9%- 66.4%); @16wks. PASI 90 87.0%- well tolerated with both doses; no new safety signals observed: P-III results @12wks. 80% achieved clear or almost clear skin & @16 wks. 87.0% achieved
- Cosentyx (secukinumab) is a novel biologic that inhibits interleukin-17A (IL-17A) targeted for psoriasis (PsO)- psoriatic arthritis (PsA) and ankylosing spondylitis (AS)
Click here to read full press release/ article | Ref: Novartis | Image:
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
